Overview

Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Dalfampridine.

Status:
Terminated
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
This is an extension study to evaluate the long-term safety, tolerability, and efficacy of two dose strengths of dalfampridine-ER.
Phase:
Phase 3
Details
Lead Sponsor:
Acorda Therapeutics
Treatments:
4-Aminopyridine